Conference Coverage
Conference Coverage
ASH: Oral drug offers alternative to lifelong transfusions in sickle cell
Key clinical point: Hydroxyurea can substitute for chronic transfusions to prevent primary stroke in children with sickle cell disease and...
Conference Coverage
ASH: Genes affecting risk, severity of chronic ITP are identified
Key clinical point: IFNA17 and IFNLR1 may be important candidate genes involved in immune regulation and sustained autoimmunity in immune...
Conference Coverage
ASH: Genes tag increased risk for avascular necrosis in ALL patients under age 10
Key clinical point: Gene profiles can identify ALL patients under age 10 at increased risk for avascular necrosis. Major finding: In children...
Conference Coverage
VIDEO: Gene therapy repairs immune function in older patients with SCID-XI
Conference Coverage
ASH: Pill bottles flag noncompliance in patients on ALL maintenance
Key clinical point: Patients in first ALL remission may not be as adherent to 6MP maintenance therapy as they claim. Major finding: In all, 40.4%...
Conference Coverage
ASH: Genes, induction response identify high risk childhood B-lymphoblastic leukemia patients with good outcomes
Key clinical point: Knowing which patients would not benefit from further intensification of their chemotherapy might spare them possible toxicity...
Conference Coverage
ASH: Longer-stored RBCs equivalent to shorter for children with severe anemia
Red blood cells stored for up to 35 days were not inferior to more recently collected RBCs for tissue reoxygenation.
Conference Coverage
ASH: Gene therapy restores immune function to older children with SCID-X1
The first two patients treated had enhanced expression of B, T, and NK cells, with the cells continuing to show improvements.
Conference Coverage
ASH: Donor CAR-T cells elicit responses in mixture of progressive B-cell cancers
Key clinical point: Allogeneic anti-CD19 CAR T-cell therapy showed promise in a treatment approach for B-cell malignancies persisting after...
Conference Coverage
ASH: Gene therapy reduces transfusion needs in beta-thalassemia major
Lentiviral-based gene therapy can lead to transfusion independence in some patients with beta-thalassemia major.
Conference Coverage
ASH: Gene therapy eases effects of rare Wiskott-Aldrich syndrome
Key clinical point: Gene therapy might safely and effectively correct an inherited immunodeficiency syndrome. Major finding: Six of eight...